InnaVirVax Press Release on World AIDS Day
December 16, 2012
InnaVirVax: the Phase I/IIa clinical study of its VAC-3S immunotherapeutic vaccine in the treatment of HIV infection has achieved its primary endpoint
December 16, 2012
InnaVirVax: the Phase I/IIa clinical study of its VAC-3S immunotherapeutic vaccine in the treatment of HIV infection has achieved its primary endpoint